Delivery Order SPE2DB20D2014-SPE2DB25FC89C
- Not listed
- The Defense Logistics Agency awarded a $29,794.79 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a $40,681.37 firm fixed price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This non-set-aside contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a $38,968.29 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This is a firm fixed price, non-set-aside delivery order with performance through September 5, 2025, and fulfillment from the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $53,305.92 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a delivery order, this award is a child contract executed under a larger...
- The Defense Logistics Agency awarded a delivery order valued at $30,206.63 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed price, non-set-aside contract is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency (DLA) for Dupixent 200 mg/1.14 ml pen auto-injectors. The contract is valued at $1,935.84 with a firm fixed price structure and an ultimate completion date of August 5, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $13,364.64 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injections on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price, non-competitive delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's facility...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC89CDelivery Order
The Defense Logistics Agency awarded a $83,783.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of September 4, 2025. This competitively awarded contract, with no set-aside designation, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company has demonstrated substantial capability in fulfilling federal pharmaceutical supply requirements through numerous competitively awarded contracts with DLA, encompassing a comprehensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This delivery order for Dupixent, a biologic immunosuppressant used to treat conditions including atopic dermatitis and asthma, reflects the company's ongoing role as a primary source for specialty pharmaceutical support to military medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $83.8k | 9/3/25 |